TriangleNCT01209325 · REGISTRY CONDITION SEARCH
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2020-08-11
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA
Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 11 DNA
Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 16 DNA
Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 18 DNA
Incidence of Persistent Anogenital Infection With HPV 6 DNA
Incidence of Persistent Anogenital Infection With HPV 11 DNA
Incidence of Persistent Anogenital Infection With HPV 16 DNA
Incidence of Persistent Anogenital Infection With HPV 18 DNA
Incidence of HGAIN Associated With HPV 6
Incidence of HGAIN Associated With HPV 11
Incidence of HGAIN Associated With HPV 16
Incidence of HGAIN Associated With HPV 18
Incidence of Penile/Scrotal Condyloma in HPV 6 Naive and Prior Exposed Participants
Incidence of Penile/Scrotal Condyloma in HPV 11 Naive and Prior Exposed Participants
Incidence of Penile/Scrotal Condyloma in HPV 16 Naive and Prior Exposed Participants
Incidence of Penile/Scrotal Condyloma in HPV 18 Naive and Prior Exposed Participants
Occurrence of Grade ≥ 3 Adverse Events (AEs) That Were Possibly, Probably, or Definitely Related to the Vaccine
Geometric Mean Titers for HPV 6
Geometric Mean Titers for HPV 11
Geometric Mean Titers for HPV 16
Geometric Mean Titers for HPV 18
Geometric Mean Titers for HPV 6 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level
Geometric Mean Titers for HPV 11 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level
Geometric Mean Titers for HPV 16 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level
Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- DISEASE CHARACTERISTICS: * Men with a history of at least one male sexual partner * "Men" is defined as those documented "male" at birth (including male-to-female transgendered persons) * HIV-1 infection as documented by any federally approved, licensed HIV test performed in conjunction with screening (ELISA, western blot, or other approved test) * Alternatively, this documentation may include a record that another physician has documented that the patient has HIV based on prior ELISA and western blot, or other approved diagnostic tests * Meets one of the following sets of criteria: * Patients receiving antiretroviral therapy: * Receipt of antiretroviral therapy for at least 3 months prior to entry * No change in antiretroviral therapy within 30 days prior to entry * Patients not receiving antiretroviral therapy: * CD4-cell count ≥ 350 cells/mm³ within 90 days prior to study entry * No plans to start antiretroviral therapy prior to Week 28 * Normal anal cytological result, LSIL/condyloma, or ASCUS result within 90 days prior to entry, and no HGAIN on biopsy * No current or history of anal or peri-anal carcinoma * No anal cytological result of HSIL, atypical squamous cells suggestive of HSIL (ASC-H), or suggestive of invasive carcinoma at screening; or history of these results * No presence of penile or scrotal condyloma, LGAIN (condyloma or AIN 1), HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3), or invasive carcinoma at pre-entry on biopsy * No history of HGAIN PATIENT CHARACTERISTICS: * Karnofsky performance score ≥ 70 within 45 days prior to entry * Absolute neutrophil count (ANC) \> 750 cells/mm\^3 * Hemoglobin ≥ 9.0 g/dL * Platelet count ≥ 100,000/mm\^3 * AST (SGOT), ALT (SGPT) ≤ 3 times upper limit of normal (ULN) * Total or conjugated (direct) bilirubin ≤ 2.5 times ULN within 45 days before study entry, with the exception of isolated hyperbilirubinemia that is considered due to atazanavir * Calculated creatinine clearance ≥ 60 mL/min * No hemophilia * No active drug or alcohol use or dependence that, in the opinion of the site Investigator, would interfere with adherence to study requirements * No serious illness requiring systemic treatment and/or hospitalization within 45 days prior to entry * No serious medical or psychiatric illness that, in the opinion of the site Investigator, will interfere with the ability of the subject to give informed consent or adhere to the protocol * No allergy to yeast or any of the components of Gardasil PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior splenectomy * No prior receipt of Gardasil or other HPV vaccine * No use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids for greater than 14 days, investigational vaccines, interleukins, interferons, growth factors, or IVIG within 45 days prior to study entry * No expected use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids used for greater than 14 days, investigational vaccines, interleukins, interferons, growth factors, or IVIG during study followup * No patients with hepatitis C who expect to initiate treatment for hepatitis C (e.g., interferons) during this trial * Not currently receiving anticoagulation therapy other than acetylsalicylic acid
- healthy Volunteers
- false
- maximum Age
- 26 Years
- minimum Age
- 13 Years
- sex
- MALE
- std Ages
- CHILD
- ADULT
Treatment arms and interventions
- arm Groups
- description
- Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
- intervention Names
- Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- Other: laboratory biomarker analysis
- label
- Vaccination
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Vaccination
- name
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
- type
- BIOLOGICAL
- arm Group Labels
- Vaccination
- name
- laboratory biomarker analysis
- type
- OTHER
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- PREVENTION
Enrollment
- count
- 149
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 6 positive DNA in participants without HPV-6 related AIN at baseline.
- measure
- Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA
- time Frame
- Post Month 7 through Month 24
- description
- Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 11 positive DNA in participants without HPV-11 related AIN at baseline.
- measure
- Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 11 DNA
- time Frame
- Post Month 7 through Month 24
- description
- Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 16 positive DNA in participants without HPV-16 related AIN at baseline.
- measure
- Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 16 DNA
- time Frame
- Post Month 7 through Month 24
- description
- Incident events are defined as having AIN (e.g., AIN or anal/perianal condyloma) with HPV 18 positive DNA in participants without HPV-18 related AIN at baseline.
- measure
- Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 18 DNA
- time Frame
- Post Month 7 through Month 24
- description
- Incident events are defined as having HPV 6 positive PCR results at 2 or more consecutive visits in those who were DNA negative for HPV 6. Persistence was defined based on being persistent in the same anatomical site.
- measure
- Incidence of Persistent Anogenital Infection With HPV 6 DNA
- time Frame
- Post Month 7 through Month 24
- description
- Incident events are defined as having positive PCR results with HPV 11 at 2 or more consecutive visits in those who were DNA negative for HPV 11 at baseline. Persistence was defined based on being persistent in the same anatomical site.
- measure
- Incidence of Persistent Anogenital Infection With HPV 11 DNA
- time Frame
- Post Month 7 through Month 24
- description
- Incident events are defined as having positive PCR results with HPV 16 at 2 or more consecutive visits in those who were DNA negative for HPV 16 at baseline. Persistence was defined based on being persistent in the same anatomical site.
- measure
- Incidence of Persistent Anogenital Infection With HPV 16 DNA
- time Frame
- Post Month 7 through Month 24
- description
- Incident events are defined as having positive PCR results with HPV 18 at 2 or more consecutive visits in those who were DNA negative for HPV 18. Persistence was defined based on being persistent in the same anatomical site.
- measure
- Incidence of Persistent Anogenital Infection With HPV 18 DNA
- time Frame
- Post Month 7 through Month 24
- description
- Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 6 positive DNA in participants without HPV 6 related HGAIN at baseline.
- measure
- Incidence of HGAIN Associated With HPV 6
- time Frame
- Post month 7 through month 24
- description
- Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 11 positive DNA in participants without HPV 11 related HGAIN at baseline.
- measure
- Incidence of HGAIN Associated With HPV 11
- time Frame
- Post month 7 through month 24
- description
- Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 16 positive DNA in participants without HPV 16 related HGAIN at baseline.
- measure
- Incidence of HGAIN Associated With HPV 16
- time Frame
- Post month 7 through month 24
- description
- Incident events are defined as having HGAIN (e.g., AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3) with HPV 18 positive DNA in participants without HPV 18 related HGAIN at baseline.
- measure
- Incidence of HGAIN Associated With HPV 18
- time Frame
- Post month 7 through month 24
- secondary Outcomes
- description
- Number of participants who experienced grade 3 and higher AEs that were possibly, probably or definitely related to the vaccine.
- measure
- Occurrence of Grade ≥ 3 Adverse Events (AEs) That Were Possibly, Probably, or Definitely Related to the Vaccine
- time Frame
- Through Month 24
- description
- Geometric mean concentration of antibodies for HPV 6 at each visit
- measure
- Geometric Mean Titers for HPV 6
- time Frame
- Baseline through month 24
- description
- Geometric mean concentration of antibodies for HPV 11 at each visit
- measure
- Geometric Mean Titers for HPV 11
- time Frame
- Baseline through month 24
- description
- Geometric mean concentration of antibodies for HPV 16 at each visit
- measure
- Geometric Mean Titers for HPV 16
- time Frame
- Baseline through 24 months
- description
- Geometric mean concentration of antibodies for HPV 18 at each visit
- measure
- Geometric Mean Titers for HPV 18
- time Frame
- Baseline through 24 months
- description
- Geometric mean concentration of antibodies for HPV 6 at 7 and 24 months
- measure
- Geometric Mean Titers for HPV 6 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level
- time Frame
- at 7 and 24 Months
- description
- Geometric mean concentration of antibodies for HPV 11 at 7 and 24 months
- measure
- Geometric Mean Titers for HPV 11 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level
- time Frame
- at 7 and 24 Months
- description
- Geometric mean concentration of antibodies for HPV 16 at 7 and 24 months
- measure
- Geometric Mean Titers for HPV 16 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level
- time Frame
- at 7 and 24 Months
- description
- Geometric mean concentration of antibodies for HPV 18 at 7 and 24 months
- measure
- Geometric Mean Titers for HPV 18 According to Participant Age, HIV Viral Load, CD4+ T Cell Count, and Nadir CD4 Level
- time Frame
- at 7 and 24 Months
Full study description
- brief Summary
- RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.
- detailed Description
- OBJECTIVES: Primary * To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing penile/scrotal condyloma and HPV-6, -11, -16, -18- associated perianal/anal disease in HIV-positive males who have sex with males (MSM) age 13-26 years by comparing the incidence of these lesions among those naïve to the relevant HPV type(s) at baseline to those who are not naïve at baseline. * To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing persistent anogenital infection with HPV-6, -11, -16, or 18 in HIV-positive MSM age 13-26 years by comparing the incidence of persistent infection among those naïve to the relevant HPV type(s) at baseline to those who are not naïve at baseline. * To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing anogenital lesions associated with HPV 6,-11,-16, -18 and persistent infection with these types, in HIV-positive MSM age 13-26 years by comparing the incidence of lesions and persistent infection among those naïve to the relevant types at baseline to incident lesions and infection among MSM naïve to these HPV types who participated in the Merck 020 protocol and who received placebo as part of the protocol. Secondary * To define the safety of the HPV-6, -11, -16, -18 vaccine in HIV-positive MSM age 13-26 years. * To evaluate the levels and persistence of HPV 6, 11, 16 and 18 Ab titers after the vaccination series among subjects who are seropositive and seronegative at baseline. * To examine whether the protective effect and antibody titers vary as a function of the following at the time of initial vaccination: subject age, HAART treatment status, HIV viral load, CD4 + T-cell count, and nadir CD4 level. Tertiary * To quantify anogenital HPV DNA viral load prior to and after receipt of the quadrivalent HPV vaccine. * To identify and quantify HPV types in the oral cavity of HIV-positive MSM prior to and after receipt of the quadrivalent HPV vaccine. * To identify HPV strain variants among HIV-positive participants prior to and after receipt of the quadrivalent HPV vaccine. * Assess the prevalence and incidence of urinary and gonorrhea and Chlamydia trachomatis infection at baseline and their relationship with prevalent and incident anogenital HPV infection and anal condyloma or AIN. * To characterize young men's risk perceptions, sexual behaviors, and STI diagnosis after HPV vaccination. OUTLINE: This is a multicenter study. Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine intramuscularly on day 1 and in weeks 8 and 24. Blood and tissue samples may be collected periodically for laboratory studies. After completion of study treatment, patients are followed up for 2 years.
Source references
- references
- citation
- Kahn JA, Belzer M, Chi X, Lee J, Gaur AH, Mayer K, Martinez J, Futterman DC, Stier EA, Paul ME, Chiao EY, Reirden D, Goldstone SE, Ortiz Martinez AP, Cachay ER, Barroso LF, Da Costa M, Wilson CM, Palefsky JM; AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions. Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men. Papillomavirus Res. 2019 Jun;7:52-61. doi: 10.1016/j.pvr.2019.01.002. Epub 2019 Jan 15.
- pmid
- 30658128
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-5e50092a1b5b49a0d347
- requested nct id
- NCT01209325
- primary nct id
- NCT01209325
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- e9517ade36d469a7fd2e8b9c24ac926bac342fd6e763013a79e66e2d510f9bb7
- payload sha256
- d2b89fc25c80dea4f93b00c75f758bd9e5a9fe16f006a17f2de101238470b3ac
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-5e50092a1b5b49a0d347
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT01209325
- occurrences
- context exact
- NCT01209325
- end
- 11
- exact text
- NCT01209325
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Penile Cancer
- query disease state id
- ds-penile-cancer
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-penile-cancer-000.json
- source file sha256
- e9517ade36d469a7fd2e8b9c24ac926bac342fd6e763013a79e66e2d510f9bb7
- source json pointer
- /studies/10/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 50ee29c4d57cf9ec3c88c0bd060f2939efa49e4456c60bc19fe8301c8bfb80ef
Preserved source evidence · Not medical advice